Conferences
ESMO 2017: ARASENS: A Phase 3 Trial of Darolutamide in Males with Metastatic Hormone-Sensitive Prostate Cancer
September 10, 2017
ESMO 2017: Phase I study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer
September 10, 2017
ESMO 2017: Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence enhancement and tumor inhibition in advanced prostate cancer
September 10, 2017
ESMO 2017: DNA repair gene panel mutations in young onset and aggressive v non-aggressive prostate cancer cases in the UK
September 10, 2017
ESMO 2017: Ramucirumab plus docetaxel improves progression-free survival in urothelial cancer
September 10, 2017
ESMO 2017: Mature results favour pembrolizumab as second-line treatment for bladder cancer
September 10, 2017
ESMO 2017: Panel Discussion – Targeted Alpha Therapy
September 9, 2017
ESMO 2017: The Future of Targeted Alpha Therapy
September 9, 2017
ESMO 2017: The Evolving Landscape of Treating Advanced Prostate Cancer
September 9, 2017